Avandia Should Stay On Market, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint advisory committee concludes, however, that the thiazolidinedione raises cardiovascular risk.
You may also be interested in...
Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010
Accumulating negative information about the cardiovascular risks of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone) led a much larger number of FDA advisory panel members to recommend taking it off the market than when the same committees met three years earlier
Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010
Accumulating negative information about the cardiovascular risks of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone) led a much larger number of FDA advisory panel members to recommend taking it off the market than when the same committees met three years earlier
Avandia Day Two Might Be Same Old Song Even With Broken RECORD
There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.